Anaspec has introduced the monoclonal antibody anti-5-methylcytidine (Clone 33D3) for use in epigenetics research.
Purified from ascites, this IgG1/isotype antibody is supplied as a 1mg/ml solution (in PBS) and is available in three sizes (0.1mg, 0.5mg and 1mg).
The company said 5-methylcytidine is a modified base found in the DNA of plants and vertebrate.
DNA methylation is a post-replication process involved in the establishment of genomic imprinting, in the control of gene expression and of differentiation.
Alterations of DNA methylation pattern are associated with carcinogenisis.
A global DNA hypomethylation is often detected in tumour tissues, associated with local hypermethylation sites.
Since this antibody discriminates between the modified base 5-MeCyd and its normal counterpart cytosine, it is a useful tool for gene promoter methylation analysis.
The most published anti 5-methylcytidine antibody available on the market, anti-5-methylcyidine from Clone 33D3 can be used in applications such as Methylated DNA Immunoprecipitation (MeDIP), MeDIP-on-chip assay, immunofluorescence, flow cytometry and immunohistochemistry.
Histopathological analysis of tissue samples can be performed without having to destroy cells through DNA extraction procedures.
This antibody has been used to detect alterations in the urinary excretions of nucleosides from cancer patients, to visualise the distribution of methyl-rich regions along human chromosomes, to quantify in situ differences between normal and malignant cells from peripheral blood as well as on tissue sections.
